Market Overview

Baxalta Submits Marketing Application For Adynovi In Europe, Shares Tick Higher


Shares of Baxalta Inc (NYSE: BXLT) were trading higher by nearly 1 percent Wednesday after the company announced it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval of its ADYNOVI.

Baxalta completed a study in patients aged 12 to 16 and its EMA filing is based on data from three Phase 3 clinical trials. ADYNOVI is already licensed in the U.S. as ADYNOVATE and under regulatory review in Japan, Canada and Switzerland.

''We are dedicated to bringing ADYNOVI to hemophilia A patients all over the world,'' said Brian Goff, executive vice president and president, Hematology, Baxalta. ''As we build on our market-leading portfolio of direct factor replacement treatments, we continually bring new options to hemophilia patients, empowering them to manage their hemophilia, with their caregivers, in the way that works best for them.''

Posted-In: ADYNOVATE ADYNOVI Baxalta Brian GoffNews


Related Articles (BXLT)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at